期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型抗深部真菌感染药物——棘白霉素类 被引量：7

New Anti-deep Fungus Infection Drugs: Echinocandins
下载PDF
导出
摘要 棘白霉素类(卡泊芬净、米卡芬净、阿尼芬净)抗真菌药是最新型的1种广谱抗真菌药,作用于真菌细胞壁,对于念珠菌属以及曲霉菌属均有效,使用安全性较高。该文主要综述了棘白霉素类药物的作用机制、适应证、抗菌谱、药动学、药物相互作用及不良反应。 The echinocandins（caspofungin,micafungin,and anidulafungin） are the new class of anti-fungal compounds that target the fungal cell wall,and these agents have a broad spectrum of activity against Candida,Aspergillus Species,etc.This paper provides a summary of the mechanism of action,indications,antimicrobial activity,pharmaco- kinetics,drug interaction and adverse reactions.
作者 赵静 钱继岳 邢振堂 王福生 郝文化 孟雅娟
机构地区 华北制药集团新药研究开发有限责任公司
出处 《抗感染药学》 2011年第1期8-10,共3页 Anti-infection Pharmacy
关键词 棘白霉素 卡泊芬净 米卡芬净 阿尼芬净 真菌感染 echinocandins caspofungin micafungin anidulafungin fungal infections
分类号 R978.7 [医药卫生—药品]
  • 相关文献

参考文献18

  • 1David S,Perlin.Resistance to echinocandin-class anti-fungal drugs[J].Drug Resist Updat,2007,10(3): 121 - 130.
  • 2T M Hohl,M Feldmesser, et al.Caspofungin modulates inflammatory esponses to aspergillus fumigatus through- stage-specific effects on fungal β-glucan exposure[J].Inect Dis,2008,198(2): 176-185.
  • 3Kauffrnan CA, Carver PL. Update on echinocandin anti- fungals[J].Semin Respire Crit Care Med, 2008, 29(2): 211-219.
  • 4Arnaldo L. Colombo, Angela L, et al. Caspofungin use inpatients with invasive candidiasis caused by common non-albicans candida species: review of the caspofungin database[J].Antimicrobial Agents and Chemotherapy, 2010, 54(5):1864-1871.
  • 5Walsh T J, Teppler H, Donowitz G R, et al. Caspofunginversus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia [J].J New Engl Medicine,2004,351 ( 14): 1391.
  • 6Seiji H. Micafungin:a sulfated echinocandins micafungin [J].J Antibiotics, 2009(62):27-35.
  • 7乔建军,刘伟,万喆,李若瑜.米卡芬净对分离自中国的念珠菌和曲霉临床株体外抑菌活性的研究[J].中国真菌学杂志,2007,2(1):5-9. 被引量：25
  • 8Kristina E,Estes. Pharmacology and antifungal properties of anidulafungin,a newechinocandin[J].Pharm D, 2009, (29):19-30.
  • 9Shawn A,Messer. Activity of contemporary antifungal agents,including the novel eehinocandin anidulafungin, tested against candida spp., cryptococcus spp. and aspergillux spp.: report from the sentry antimicrobial surveillance Program (2006-2007)[J].J Clin Mierob, 2009.
  • 10M A,Pfaller L,Boyken, et al. In Vtro susceptibility of clinical isolates of aspergillus spp. to anidulafungin,caspofungin,and micafungin: a head-to-head comparison using the clsi m38-a2 broth microdilution method[J]. J Clin Microb, 2009, 47(10):3323-3325.

二级参考文献37

  • 1陈端,单斌,骈淮燕,杜艳,郭翀.医院真菌感染1225例分析[J].中华检验医学杂志,2005,28(4):387-388. 被引量：44
  • 2李若瑜,刘伟,乔建军.烟曲霉对唑类抗真菌药物耐药的分子机制研究现况[J].中国处方药,2006,5(3):38-41. 被引量：4
  • 3Andriole V T. Current and future antifungal therapy: new targets for antifungal therapy[J ]. Int J Antimierob Agents, 2000, 16: 317.
  • 4Denning D W. Echinocandin antiftmgal drugs[J ]. Lancet, 2003, 362: 1142.
  • 5Ashley E S D, Lewis R, Lewis J S, et al. Pharmacology of Systemic Antifungal Agents[]]. Clin Infect Dis, 2006, 43: S28.
  • 6Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaeonazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature[J]. Rev Iberoarn Micol, 2003, 20(4) : 121.
  • 7Theuretzbacher U. Pharmacokineties/pharmacodynamics of echinocandins[J]. Eur J Clin Microbiol Infect Dis, 2004, 23 (11): 805.
  • 8Hebert M F, Smith H E, Marbury T C, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction [J]. J Clin Pharmacol, 2005, 45(10): 1145.
  • 9Thye D, Kilfoil T, White K, et al. Anidulfuugin: pharmacokinetics in subjects with mild and moderate hepatic impairment. Proceeding of 41th Interseiences conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM [ M ]. Chicago, 2001: 459.
  • 10Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model[J]. Antimicrob Agents Chemother, 2003, 47 (4) : 1193.

共引文献32

同被引文献51

  • 1曹国颖,傅得兴.新型棘白菌素类抗真菌药阿尼芬净[J].中国新药杂志,2005,14(11):1358-1361. 被引量：15
  • 2蒋正立,林建群.多烯类抗真菌药物的研究新进展[J].中国药业,2006,15(7):62-63. 被引量：16
  • 3陈頔,曹国颖,傅得兴,孙春华.棘白霉素类抗真菌药的研究进展[J].中国新药杂志,2007,16(14):1082-1087. 被引量：15
  • 4汪复,张婴元.使用抗感染治疗学.北京:人民卫生出版社.353-362.
  • 5陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:85-86.
  • 6DEBON O M, GORDEE R S. Antibiotics that inhibit fungal cell wall development[J]. Annu Rev Microbiol, 1994, 48 ( 12 ) : 471- 497.
  • 7MURDOCH D, PLOSKER G L. Anidulafungin[J]. Drug, 2004,64 (19) :2249-2258.
  • 8Bergogne-Berezin E. Anidulafungin, a new antifungal drug[J]. Antibiotiques, 2007, 9(3): 212-215.
  • 9Shao L, Li J A, Liu A J, of echinocandin B to its et al. Efficient bioconversion nucleus by overexpression of deacylase genes in different host strains[J]. Appl Environ Microbiol, 2013, 79(4): 1126-1133.
  • 10李继安,陈代杰,卢亮,等.棘球白素B母核的分离方法:CN.102336817A[P].2012-02-01.

引证文献7

二级引证文献14

抗感染药学
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部